Open Alliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Open Alliance
A round table with Catalent and BASF on their new collaboration to provide bioavailability solutions.

Pharmaceutical Technology Europe
Volume 24, Issue 9

Widmann: Our Kolliphor® range of products, including poloxamers, hydrogenated castor oil, TPGS and others offers a wide variety of properties that match the physicochemical properties of active ingredients. The latest innovation in this field is Soluplus®, which won the Silver CPhI Innovation Award in 2010.

Q. Hot-melt extrusion is one potential solution for resolving bioavailability issues. Can you provide details on the companies' expertise in this area?

Widmann: BASF is a recognized world-leading manufacturer and innovator of pharmaceutical excipients. We offer a line of polymers designed specifically to increase solubility in general and for use with hot-melt extrusion in particular. We have significant investments year on year in the development of pharmaceutical excipients because we believe that today's formulation challenges can not be solved with yesterday's excipients. Furthermore, BASF has decades of experience in the hot-melt extrusion technology in plastics as well as in pharmaceutical applications.

Muir: Catalent is the world-leading solubility solutions provider, with Softgel and OptiMelt™ hot-melt extrusion. Its capabilities range from development, formulation, pilot, commercial manufacturing to differentiated drug delivery on a global scale.

Q. Will BASF and Catalent staff jointly work on a project for a given client?

Muir: Catalent will cooperate with BASF to optimize solubility from excipient selection, formulation, process technology to drug delivery and dosage form for customers desiring an integrated approach. By providing our customers with the option of working with a team of experts across our companies, we will increase efficiencies for them from development to scale-up to commercial, hence enabling them to deliver more products to market.

Widmann: Nobody knows our products better than we do. This know-how in the application of our excipients is brought into the alliance by training and supporting the Catalent formulation experts. Where appropriate, experts of both companies will work together on customer projects to find optimal solutions.

Q. What feedback have you received since the collaboration began?

Widmann: The announcement generated a lot of interest in the market because every formulator is concerned about the solubility challenge.

Muir: Not only in the market, but also internally, everybody is excited about the opportunity to jointly cover the whole pharmaceutical value chain from excipients to finished drugs.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology Europe,
Click here